Cytori Therapeutics, Inc.

Company Details:

Company Symbol: CYTX
Sector: Healthcare & Medical Devices
Company Rating:
URL: http://www.cytori.com/

Related Research

  • 08/07/17 Morning Note B. Riley AM Note: AMC, AOSL, ARTX, AUXO, CNK, CYTX, DRAD, NLST, ON, NVDA, PRMW, RELY, VPG, VRS, VSAT; Internet (APPS, GDDY, TRUE)
  • 07/25/17 Update CYTX ($0.48, Neutral; $0.50 PT): STAR Misses Primary & Secondary Endpoints, But a Promising Subgroup Emerged; Unknowns/Lack of Capital Result in Us Downgrading/Lowering PT to Neutral/$0.50
  • 07/25/17 Morning Note B. Riley AM Note: AMAT, CYTX, DHX, GOOGL, GPX, JCP, KTOS, PCMI, RELY; Marine (BC, HZO, MBUU, MCFT, MPX)
  • 06/01/17 Morning Note B. Riley AM Note: ADI, CYTX, SMTC, ZUMZ; June Focus List (BV, CARB, DKS, IMAX, KTOS, LITE, MPAA, MRVL, OOMA, TRUE)
  • 05/12/17 Update CYTX ($0.94, Buy; $2.30 PT): 1Q17 Comes in Light, But Guidance was Reaffirmed; We Like the Tech But Note the Current Operating Business is Choppy; Maintaining Buy Rating & $2.30 PT
  • 05/12/17 Morning Note B. Riley AM Note: AOSL, CHKE, CYTX, DCO, DKS, FL, HIBB, IDCC, INPX (downgrade), INTC, MCFT, MRVL, ON, RELY, UFAB, VIVE, WYY
  • 05/10/17 Morning Note B. Riley AM Note: ACIA, ARTX, AUXO, CAMT, CVRS, CVU, CYTX, EKSO, FARM, HEAR, III, IVAC, JCP, MCHP, NAME, NMRX, NVDA, NVTR, PCTI, PRMW, REIS, TRUE, TST, VPG, XOXO, YELP; Boardsport (DECK, NKE, VFC)
  • 05/10/17 Update CYTX ($0.94, Buy; $2.30 PT): Q1 Preview: Revising Model Down, Believe Management Needs to Regain Street Credibility; Maintaining Buy Rating But Lowering PT from $6.75 to $2.30
  • 04/04/17 Morning Note B. Riley AM Note: BLKB, CYTX, DHX.B, FNJN, HAS (initiation), INPX, IPAR, PVH (initiation), SLAB; Media (AMC, CNK, IMAX, MCS, NCMI, RDI, RGC)
  • 03/24/17 Morning Note B. Riley AM Note: ACLS, AMAT, AMC, CYTX, FORM, HDSN, LRCX, OXM, SCVL, STMP, SUP (upgrade), TNDM (downgrade)
  • 03/24/17 Update CYTX ($1.64, Buy; $6.75 PT): 4Q16 Results Compare Favorably to RILY Estimates, Management Highlights Numerous Catalysts & Diversified Business; Maintaining Buy Rating & $6.75 PT
  • 03/20/17 Morning Note B. Riley AM Note: ARC (resuming coverage), CYTX, GSM, LOV, RTEC; Exhibitors (AMC, CNK, IMAX, MCS, RDI, RGC), The Weiser Consumer (EL, IPAR, NTRI, PG, PRGO)
  • 03/20/17 Update CYTX ($1.65, Buy; $6.75 PT): 4Q16 Preview: Q4 Estimates Seem Reasonable, Also Expecting Additional Color on Azaya Acquisition & Initial 2017 Outlook; Maintaining Buy Rating & $6.75 PT
  • 02/16/17 Update CYTX ($1.99, Buy; $6.75 PT): CYTX Diversifies its Business Through the Acquisition of Azaya Therapeutics, Inc.; Increasing PT to $6.75 from $5.75
  • 02/16/17 Morning Note B. Riley AM Note: ADI, AMAT, CFMS, CYTX, GDDY, GRPN, MAMS, MCHP, SONS, TIVO
  • 01/20/17 Morning Note B. Riley AM Note: CYTX, IIVI, SWKS; Internet (GOOGL, YHOO)
  • 12/29/16 Morning Note B. Riley AM Note: CYTX
  • 12/16/16 Update CYTX (B. Riley & Co. Initiation: $1.44, Buy; $5.75 PT): Strengthening its “Grip” on Adipose Derived Regenerative Cell Therapies; Initiating Coverage with a Buy & $5.75 Price Target
  • 12/16/16 Morning Note B. Riley AM Note: CAMP, CYTX (initiation), EXAR, FINL, IDCC, JBL, NKE, PCOM